StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Other Respiratory & Immunology medicines by Quarter

Other Respiratory & Immunology medicines — US YoY (%) (%)

QuarterlyAnnual

AstraZeneca Other Respiratory & Immunology medicines: -55.0% in Q2 2026, down 20.0 pts from a year earlier.

Latest, Q2 2026
-55.0%
Period ended Jun 30, 2026
Change on a year earlier
-20.0 pts
-35.0% in Q2 2025
History
18 quarters
Since Q4 2020
Sources
18
Documents cited below

Where the Q2 2026 figure comes from

“|| Other R&I | 69 | | 13 | | 9 | | 7 | | ( 55 ) | | 27 | | ( 1 ) | | ( 8 ) | | 33 | | n/m | | n/m | | 2 | | 6 | | 5”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOther Respiratory & Immunology medicines — US YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 2026-55.0%-20.0 ptsForm 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 2026-81.0%-118.0 ptsForm 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025-92.0%–Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025-12.0%+42.0 ptsForm 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025-35.0%+17.0 ptsForm 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 202537.0%+78.0 ptsForm 6-K FY2025Q1 Earnings Release ↗
Q3 2024Sep 30, 2024-54.0%+1.0 ptsForm 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 2024-52.0%-17.0 ptsForm 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024-41.0%+3.0 ptsForm 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 2023-26.0%-6.0 ptsForm 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 2023-55.0%-50.0 ptsForm 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 2023-35.0%-125.0 ptsForm 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 2023-44.0%-91.0 ptsForm 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 2022-20.0%–Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 2022-5.0%–Form 6-K FY2022Q3 Earnings Release ↗
Q2 2022Jun 30, 202290.0%–Form 6-K FY2022Q2 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Other Respiratory & Immunology medicines (%), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-other-ri-us-yoy

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.